A Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects with Primary Biliary Cirrhosis


About this study

The purpose of this study is to evaluate the effects of two doses of MBX-8025 in patients with primary biliary cirrhosis and an inadequate response to ursodeoxycholic acid

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Must have given written informed consent (signed and dated) and any authorizations required by local law
  • 18 to 75 years old (inclusive)
  • Male or female 
  • Has a diagnosis of primary biliary cirrhosis, by at least two of the following criteria
    • History of AP above upper limits of normal for at least six months
    • Positive Anti-Mitochondrial Antibodies (AMA) titers (>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies
    • Documented liver biopsy result consistent with PBC
  • On a stable and recommended dose of ursodeoxycholic acid for the past twelve months
  • AP ≥ 1.67 × ULN
  • Females of reproductive potential must use at least one barrier contraceptive and a second effective birth control method during the study and for at least two weeks after the last dose
  • Male subjects must use appropriate contraception (e.g., condoms) so their female partners of reproductive potential do not become pregnant during the study and for at least two weeks after the last dose

Exclusion Criteria

  • A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer on active treatment)
  • AST or ALT > 3 × ULN
  • Total bilirubin > 2 × ULN
  • Auto-immune hepatitis
  • Primary sclerosing cholangitis
  • Known history of alpha-1-Antitrypsin deficiency
  • Known history of chronic viral hepatitis
  • Creatine kinase above ULN
  • Serum creatinine above ULN
  • For females, pregnancy or breast-feeding
  • Use of colchicine, methotrexate, azathioprine, or systemic steroids in the two months preceding screening
  • Current use of fibrates, including fenofibrates, or simvastatin
  • Use of an experimental treatment for PBC
  • Use of experimental or unapproved immunosuppressant
  • Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Elizabeth Carey, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer